Respiratory syncytial virus, or RSV, is a common infection among both infants and older people that can lead to dangerous inflammation of the lungs and contributes to up to 240,000 hospitalizations in the U.S. annually. But until this year, there wasn’t a vaccine to protect against the virus. Now, there are several. In May, the FDA approved GSK’s Arexvy for adults over age 60, and followed with approval of Abrysvo from Pfizer for the same age group. In August, the agency approved the same Pfizer vaccine for pregnant women in order to protect newborns. And kids under age two whose moms weren’t vaccinated can now take advantage of Sanofi Pasteur’s Beyfortus, a one-time, injected antibody therapy that the FDA approved in July and improves on the previous treatment that required multiple shots throughout the winter season.
- Inside Elon Musk’s War on Washington
- Why Do More Young Adults Have Cancer?
- Colman Domingo Leads With Radical Love
- 11 New Books to Read in February
- How to Get Better at Doing Things Alone
- Cecily Strong on Goober the Clown
- Column: The Rise of America’s Broligarchy
- Introducing the 2025 Closers